Bifogade filer
Kurs & Likviditet
Prenumeration
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
STOCKHOLM, SWEDEN - 14 May 2024: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby publishes an interim report for the first quarter 2024. The report is available as an attached document and on the company's website (www.modustx.com). Below is a summary of the interim report.
John Öhd, Modus Therapeutics' CEO, commented:
” After the financing that Modus Therapeutics carried out in December 2023, the focus in the first quarter of 2024 has been on carrying out planned activities within the research areas that the company deems prioritized; chronic kidney disease with anemia, sepsis and severe malaria. During the quarter, Modus worked intensively on the preparations of the phase IIa study which aims to establish proof-of-concept for the treatment effect of sevuparin in patients with anemia in kidney disease.”
The first quarter in figures
- The loss after tax amounted to TSEK 3 105 (6 040).
- The loss per share amounted to SEK 0,09 (0,38).
- The cash flow from current operations was negative in the amount of TSEK 3 665 (6 335).
Important events during the first quarter
- Modus Therapeutics participated in Swiss Nordic Bio, Zurich.
Important events after the end of the period
No event to report.
CEO John Öhd will provide comments on the report in an interview with Jonathan Furelid on May 14 at 13:00 Link to Interview: https://www.youtube.com/watch?v=plSUuV2WFdo